Canada markets closed
  • S&P/TSX

    21,216.15
    +3.76 (+0.02%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.94 (+0.21%)
     
  • CAD/USD

    0.8091
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    83.98
    +1.48 (+1.79%)
     
  • BTC-CAD

    75,700.79
    -301.95 (-0.40%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • GOLD FUTURES

    1,793.10
    +11.20 (+0.63%)
     
  • RUSSELL 2000

    2,291.27
    -4.92 (-0.21%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • NASDAQ

    15,090.20
    -125.50 (-0.82%)
     
  • VOLATILITY

    15.43
    +0.42 (+2.80%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • CAD/EUR

    0.6942
    -0.0010 (-0.14%)
     

Replimune to Present at Two Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BTIG Virtual Biotechnology Conference 2021
Date: Monday, August 9, 2021
Presentation Time: 11:00 am ET

2021 Wedbush PacGrow Healthcare Virtual Conference
Panel: For Your IOnly - Progress, Challenges in Immuno-Oncology
Date: Wednesday, August 11, 2021
Presentation Time: 12:35 pm ET

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting